Cardiac positron emission tomography (PET) imaging is a well-validated, reimbursable means to assess myocardial perfusion, left ventricular function, and viability. Presently, there is a proliferation of PET instrumentation as well as an increase in educational programs that specifically address PET imaging. Technologists performing PET scans as well as physicians interpreting them should have a sound knowledge of recommended standards for the performance, interpretation, and quality control of
Original ArticleAmerican society of nuclear cardiology practice guidelines: PET myocardial glucose metabolism and perfusion imaging☆
Section snippets
Introduction to the Guidelines
PET myocardial glucose metabolism and perfusion imaging: Part I – Guidelines for patient preparation and data acquisition
Stephen L. Bacharach, PhD, Jeroen J. Bax, MD, James Case, PhD, Dominique Delbeke, MD, Karen A. Kurdziel, MD, William H. Martin, MD, and Randolph E. Patterson, MD
References (21)
F-18-deoxyglucose and the assessment of myocardial viability
Semin Nucl Med
(2002)- et al.
Noninvasive quantification of regional myocardial flow reserve in patients with coronary atherosclerosis using nitrogen-13 ammonia positron emission tomography. Determination of extent of altered vascular reactivity
J Am Coll Cardiol
(1995) - et al.
Noninvasive quantification of regional blood-flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging
J Am Coll Cardiol
(1990) - Dilsizian V. Myocardial viability: a clinical and scientific treatise. Armonk (NY): Futura; 2000. p....
- et al.
Positron emission tomography for the assessment of myocardial viability
- Bergmann SR. Quantification of myocardial perfusion with positron emission tomography. In: Sobel BE, editor. Positron...
- Cardiogen-82 rubidium Rb-82 [package insert]. Princeton (NJ): BraccoDiagnostics;...
- et al.
A simplified method for quantification of myocardial blood flow using nitrogen-13-ammonia and dynamic PET
J Nucl Med
(1993) - et al.
13N ammonia myocardial imaging at rest and with exercise in normal volunteers. Quantification of absolute myocardial perfusion with dynamic positron emission tomography
Circulation
(1989) - et al.
Assessment of myocardial blood flow with positron emission tomography
Cited by (93)
Myocardial Viability Testing by Positron Emission Tomography: Basic Concepts, Mini-Review of the Literature and Experience From a Tertiary PET Center
2020, Seminars in Nuclear MedicineCitation Excerpt :This condition is emulated by most viability preparation protocols. In nondiabetic subjects, an oral glucose load (50 g of sugar solution) results in rapidly elevated levels of insulin and concomitantly suppressed levels of the quantitatively most important competing fuel, fatty acids.48 Insulin levels quite consistently peak after about 60 minutes,49 but the biological effects persist for at least another 30-60 minutes.
Competency-Based Medical Education: Do the Cardiac Imaging Training Guidelines Have it Right?
2019, JACC: Cardiovascular ImagingStatus of F-18 fluorodeoxyglucose uptake in normal and hibernating myocardium after glucose and insulin loading
2018, Journal of the Saudi Heart AssociationMyocardial perfusion imaging in coronary artery disease
2015, Cor et VasaCitation Excerpt :Such improvements include the ability to extract myocardial blood flow reserve and coronary flow reserve measurements [13]. PET has improved spatial resolution as 2–3 mm as compared with the 6- to 8-mm resolution of conventional SPECT imaging [14]. MPI PET has been extensively evaluated and has been shown to be both sensitive and specific for the diagnosis of CAD.
Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy
2012, Journal of Cardiac FailureCitation Excerpt :18F-FDG-PET/computerized tomographic (CT) scans were performed before and after the treatment with sitagliptin. The patient preparation was performed in accordance with the American Society of Nuclear Cardiology Practice Guidelines for oral glucose loading.34 In short, patients fasted for ≥6 hours before arrival.
- ☆
Publication supported by educational grants from Amersham Health, Inc, Bracco Diagnostics, Inc, Bristol-Meyers Squibb Medical Imaging, Inc, CardinalHealth Nuclear Pharmacy Services, Fujisawa Health Care, Inc, GE Medical Systems, Inc, MDS Nordion, Philips Medical Systems, Inc, Siemens Medical Systems, Inc, and Tyco Healthcare/Mallinckrodt.
Reprint requests: American Society of Nuclear Cardiology, 9111 Old Georgetown Rd, Bethesda, MD 20814, [email protected]